Company Overview and News

 
TVB buys US$83 million convertible bond in mainland theatre operator SMI

2018-05-03 scmp
Television Broadcasts (TVB), Hong Kong’s main free-to-air broadcaster, has bought an US$83 million (HK$651.55 million) convertible bonds in mainland cinema operator SMI Holdings Group, according to a stock exchange filing on Thursday.

 
Inside Hong Kong IPO bacchanalia

2018-03-31 thestar.com.my
Eye-popping rally: C-Mer Eye Care Holdings, an eye-clinic operator whose founder is well known for catering to Hong Kong’s rich and famous, surged as much as 586 in the first three days. — Bloomberg

 
TVB abandons stock buy-back, dealing a blow to mainland mogul’s plan to extend control

2018-01-23 scmp
Hong Kong’s main free-to-air broadcaster has withdrawn its controversial share buy-back offer, abandoning a move that would have helped mainland Chinese mogul Li Ruigang raise his stake in Television Broadcasts Limited (TVB).

 
Milestone Scientific's CompuFlo(R) Epidural System, Wand(R) STA Dental System and Cosmetic Instrument Featured in Television Broadcasts and in Premier Online News Journal

2017-11-28 marketwired
LIVINGSTON, NJ--(Marketwired - November 28, 2017) - Milestone Scientific Inc. (NYSE American: MLSS) (NYSE MKT: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that its Wand® STA Dental and CompuFlo® Epidural systems were featured in separate television news broadcasts in Pittsburgh and South Florida, respectively. In addition, news of the commercial launch of the newly developed cosmetic instrument for delivery of botulinum toxin (such as Botox® and Dysport®) was picked up by Drug Delivery Business News.

 
Andy Lau’s Wall Street style TV series Trading Floor secret weapon of Fox+ in Hong Kong

2017-11-02 scmp
Fox Networks Group Asia, the multimedia arm of American media giant 21st Century Fox, has launched its video streaming platform Fox+ in Hong Kong – the latest entrant in a market overcrowded with television content providers.

 
TVB to resume trading on Monday

2017-10-08 scmp
Shares of Television Broadcasts, Hong Kong’s dominant free-to-air broadcaster, will resume trading on Monday after the Court of First Instance quashed a ruling by the city’s securities watchdog that gave all its shareholders equal rights to vote on a proposed share buy-back.

 
TVB wins judicial review in battle with Hong Kong regulator

2017-10-04 scmp
Judge rules that non Hong Kong shareholders’ votes should be capped at 49 per cent in key buy-back vote

 
Consumer Cyclical Top Dog Gainer Libbey Surpasses National CineMedia In September

2017-09-14 seekingalpha
Libby Glass blew past National CineMedia as target price and net gain Consumer Cyclical dog favorite by analyst-estimates calculated 9/8/17.

1
MyTV Super Expands VCAS for Internet TV Deployment to Secure myTV SUPER Video Service

2017-09-14 prnewswire
AMSTERDAM, Sept. 13, 2017 /PRNewswire/ -- IBC 2017 (Booth #5.A59) -- Verimatrix, the specialist in securing and enhancing revenue for network-connected devices and services, today announced that MyTV Super Limited (formerly known as TVB.COM Limited), a member of Television Broadcasts Limited (TVB), has extended its deployment of the Verimatrix Video Content Authority System (VCAS™) for Internet TV to provide over-the-top (OTT) video security for its myTV SUPER video service launched in 2016.

 
Consumer Cyclical Dog Yield & Gains Paced By National CineMedia In August

2017-08-07 seekingalpha
National CineMedia led the July/August Consumer Cyclical dogs by analyst estimated net gains, price upside, and dividend yield, as calculated 8/1/17.

 
TVB, US-based Imagine Entertainment form US$100m joint venture to develop programmes for overseas markets

2017-07-26 scmp
Hollywood film and TV production company brings strong track record and prestige to strengthen Hong Kong broadcaster’s English programming

 
Solving TVB shares row some way off despite broadcaster increasing transparency

2017-07-06 scmp
The SFC raised its concerns during the vetting process of a US$541 million share repurchase planned by TVB

 
CMC Capital Partners closes US$600m US dollar fund

2017-07-05 scmp
CMC Capital Partners, one of China’s most influential media and entertainment investors, announced on Wednesday that it had completed fundraising for its second US dollar fund having reached its target of US$600 million.

 
Consumer Cyclical Dog Gains Topped By Barnes & Noble In June

2017-06-23 seekingalpha
Barnes & Noble led the June Consumer Cyclical dogs by analyst estimated net gains, and price upside, while Greek Organization led by dividend yield, as calculated 6/16/17.

 
How Li Ruigang, China’s ‘Rupert Murdoch’, is building a global media empire

2017-06-23 scmp
China Media Capital (CMC), mainland China’s most influential media and entertainment investor, is no stranger to overseas investment and has the ambition to build a global business empire.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...